



Samuel A Waxman

Partner, Corporate Department
samuelwaxman@paulhastings.com

Samuel Waxman is a partner in the Emerging Growth Company and Mergers and Acquisitions practices at Paul Hastings. He is based in the firm's New York office.

Mr. Waxman's practice focuses on venture capital and growth equity investment funds and emerging technology companies, and is experienced in mergers and acquisitions, securities offerings, joint ventures, and intellectual property licenses, with a particular emphasis on companies for whom technology or intellectual property is a key asset. His clients range in size from Fortune 100 firms to emerging-stage companies in such diverse industries as pharmaceuticals, medical devices, data security, mobile devices, networking equipment and biotechnology. Mr. Waxman lectures on intellectual property licensing issues at Cornell Tech, the technology-focused campus of Cornell University located in New York City.

Recent Representations

Venture Capital & Emerging Growth Companies

- Deerfield Management, in connection with various debt and minority equity investments.
- Digitalis Ventures, as outside general counsel to human and companion animal health-focused venture fund.
- Canopy Rivers, in connection with various debt and minority equity investments.
- Ascent Biomedical Ventures, in connection with various debt and minority equity investments.
- Orchestra BioMed, as outside general counsel to medical device development and licensing company.
- Blacklvy Group, in connection with various debt and minority equity investments.
- Bridge Medicines, as outside general counsel of drug discovery company

New York

T: 1(212) 318-6031
F: 1(212) 230-7831

Practice Areas

Impact and Sustainability
Intellectual Property
Life Sciences and Healthcare
Corporate
IP Transactions and Licensing
Technology, Media and
Telecommunications
Emerging Growth Companies
Mergers and Acquisitions
Internet of Things
Technology

Admissions

New York Bar

Education

University of Virginia, B.A.
1997
University of Virginia, School
of Law, J.D. 2000

Samuel A Waxman (Continued)

launched in partnership with Deerfield Management, Takeda Pharmaceutical Company and Bay City Capital, Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine.

Mergers & Acquisitions and Joint Ventures

- Deerfield Management, in connection with its early-stage therapeutic research partnerships with various elite academic institutions including The Broad Institute of MIT and Harvard, Johns Hopkins University, Harvard University, and the Dana Farber Cancer Institute.
- Canopy Growth Corporation, in connection with various M&A transactions.
- Merck & Co. in connection with various M&A transactions.
- Elanco U.S., Inc., a subsidiary of Eli Lilly and Company, in its acquisition of Boehringer Ingelheim Vetmedica's U.S. feline, canine and rabies vaccines portfolio.
- Sony Corporation in connection with various M&A transactions.

Accolades and Recognitions

- Recognized as a leading M&A, technology and intellectual property lawyer in the Financial Times Innovative Lawyers Report , Legal 500 and Chambers.
- Intellectual Asset Management's Patent 1000: The World's Leading Patent Practitioners stated, "The 'street-smart' lawyer has made the most of an outstanding transactional platform at the firm and proved his mettle on some of the biggest acquisitions/divestitures around."
- Named to the top "40 Under 40 M&A Professionals" in M&A Advisor (2012)

Speaking Engagements and Publications

- Moderator, "The Future of Venture Capital", New York Venture Summit, July 2018
- Smarter, Faster, Stronger: A New Suite of VC Model Docs, Law360, May 2018
- NYC: Municipal Benefactor to Life Sciences and Technology Venture Capital, Lexology, Nov 2017
- Plenary Session Moderator, "In Pursuit of Growth, Savings, and Return on Investment: Pharma's Quest for Innovation Partnerships", Life Sciences Summit, November 2017
- Guest Lecturer, "Life Sciences Patent Law", NYU School of Law, April 2017
- Resigning From a Board of Directors: Considerations for VC Fund Designees, Lexology, March 2017
- Panelist, Houlihan Lokey 2017 Illiquid Financial Assets Conference, March 2017
- Venture Debt: An Attractive Tool for Start-up Companies, Law360, February 2017

Samuel A Waxman (Continued)

- Making the Grade: Negotiating IP Licenses with Academic Institutions, Licensing Journal, January 2017, Vol. 37 Issue 1
- Panelist, "Dealmaking 2017: Exploring Academic-Industry Partnerships", New York Pharma Forum, January 2017
- Revisiting the CVR: The Litigation Crucible, Lexology, November 2016
- When Minority Stockholders Take Control: Recent Delaware Cases Shine a Light on Fiduciary Obligations of Controlling Shareholders, Law360, July 2016
- Legal Health Isn't Easy for Digital Health Companies, TechCrunch. April 2016.
- Post-Closing Fraud Claims in the Acquisition Context: Protecting the Seller, Lexology, February 2016
- Solving The Valuation Puzzle in Life Sciences Transactions: The Pros and Cons of the CVR, The M&A Lawyer, January 2016.
- Not Just Refrigerators and Light Bulbs: Connected Vehicles as an Extension of the Internet of Things, Lexology, April 2015.
- The Acquisition of IP Assets in Bankruptcy, Intellectual Property Magazine, July/August 2014.

Education

- University of Virginia School of Law, J.D., 2000
- University of Virginia, B.A., 1997, with Distinction

News

November 18, 2019

Cyclica & ATAI Life Sciences form Entheogenix Biosciences for Mental Health Treatment Research

July 10, 2019

DFB Healthcare to Acquire AdaptHealth Holdings

June 07, 2019

Paul Hastings Recognized in 2019 IAM Patent 1000 as One of the Most Sophisticated Patent Litigation Practices

April 19, 2019

Canopy Growth Announces Pathway to U.S. Presence with Planned \$3.4 Billion Purchase of Acreage Holdings

April 05, 2019

Offchain Labs Seeks to Advance Scalability and Privacy of Enterprise

Samuel A Waxman (Continued)

Blockchain

October 22, 2018

Deerfield Management and UNC-Chapel Hill Launch Pinnacle Hill Research Partnership

October 15, 2018

Canopy Growth to Acquire Assets of ebbu

August 06, 2018

Paul Hastings Launches PH Ignite, Its New Online Resource for the Emerging Growth Company Space

June 15, 2018

Paul Hastings Recognized in 2018 IAM Patent 1000 For Superb Track Record in Patent Litigation

May 11, 2018

Paul Hastings Practices and Lawyers Score Top Rankings in Chambers USA 2018

March 28, 2018

Deerfield Management and Vanderbilt University Launch Research Collaboration, Ancora Innovation

November 16, 2017

Deerfield Management and Johns Hopkins University Launch Early-Stage Therapeutics Research Collaboration

October 26, 2017

Broad Institute and Deerfield Management Form on Early-Stage Therapeutics Research Partnership

September 13, 2017

Phosplatin Therapeutics Announces Immuno-Oncology Collaboration with Pfizer and Merck KGaA, Darmstadt, Germany

August 08, 2017

Paul Hastings Recognized in 2017 IAM Patent 1000 for Pristine Patent Litigation Track Record

Samuel A Waxman (Continued)

June 05, 2017

Paul Hastings Practices and Lawyers Score Top Rankings in Chambers USA 2017

April 25, 2017

Paul Hastings Advises Intertrust on Launch of PatentShield

March 21, 2017

Legendary Golfer Greg Norman Partners with Authentic Brands Group

January 03, 2017

Elanco Animal Health Acquires Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio

November 01, 2016

Takeda Pharmaceutical Company, Bay City Capital and Deerfield Management Partner with Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine on Launch of Pioneering Drug Discovery Company Bridge Medicines

October 05, 2016

Elanco US Enters into Agreement to Acquire Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccine Portfolio for \$885 Million

January 06, 2016

Merck and Quartet Enter Into Strategic Agreement

April 22, 2015

Paul Hastings Adds Prominent M&A and Private Equity Duo in Hong Kong

March 02, 2015

Paul Hastings Adds M&A/Technology Transactions Partner in New York

Insights

May 10, 2018

Smarter, Faster, Stronger: A New Suite of VC Model Docs

November 21, 2017

NYC: Municipal Benefactor to Life Sciences and Technology Venture Capital

Samuel A Waxman (Continued)

March 27, 2017

Resigning From a Board of Directors: Considerations for VC Fund Designees

February 02, 2017

Venture Debt: An Attractive Tool for Startup Companies

November 15, 2016

Revisiting the CVR: The Litigation Crucible

November 04, 2016

Making the Grade: Negotiating IP Licenses with Academic Institutions

July 22, 2016

When Minority Stockholders Take Control: Recent Delaware Cases Shine a Light on Fiduciary Obligations of Controlling Stockholders

February 19, 2016

Post-Closing Fraud Claims in the Acquisition Context: Protecting the Seller

January 26, 2016

Solving The Valuation Puzzle in Life Sciences Transactions: The Pros and Cons of the CVR

April 17, 2015

Not Just Refrigerators and Light Bulbs: Connected Vehicles as an Extension of the Internet of Things

Rankings & Awards

June 07, 2019

Recognized by IAM Patent 1000 for 2019

June 15, 2018

Recognized by IAM Patent 1000 for 2018

May 15, 2018

Recognized by Chambers USA 2018

June 06, 2017

Recognized by IAM Patent 1000 for 2017

Samuel A Waxman (Continued)

June 05, 2017

Recognized by Chambers USA 2017

May 27, 2016

Recognized by IAM Patent 1000 for 2016